NASDAQ:LGVN

Longeveron Stock Insider Trading

Healthcare > Biotechnology

Buy LGVN

*Your capital is at risk

$0.80

+0.0400 (+5.26%)

At Close: Jun 03, 2026

Longeveron Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 88.46. In total, the insiders bought 5.2M and sold 465.49K LGVN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	88.46
● Buy	5.2M shares
● Sell	465.49K shares
67% Buy Activity Negligible or No Correlation
Buy Signal Medium Confidence May 01, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 88.46. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 01, 2026 Buy	Class A Common Stock A-Award	Agafonova Nataliya Chief Medical Officer	Officer	250 000 Value: $212.8K
May 01, 2026 Buy	Class A Common Stock A-Award	Blass Devin CTO & SVP Of Cmc	Officer	250 000 Value: $212.8K
May 01, 2026 Buy	Class A Common Stock A-Award	Lehr Paul T General Counsel, Secretary	Officer	250 000 Value: $212.8K
May 01, 2026 Buy	Class A Common Stock A-Award	Willard Stephen H Chief Executive Officer	CEO / President	500 000 Value: $425.5K
May 01, 2026 Buy	Class A Common Stock A-Award	Locklear Lisa Chief Financial Officer	C-Suite Officer	250 000 Value: $212.8K
Apr 01, 2026 Sell	Class A Common Stock F-InKind	Blass Devin CTO & SVP Of Cmc	Officer	8 633 Value: $10K
Apr 01, 2026 Sell	Class A Common Stock F-InKind	Locklear Lisa Chief Financial Officer	C-Suite Officer	13 145 Value: $14.7K
Apr 01, 2026 Sell	Class A Common Stock F-InKind	Lehr Paul T General Counsel, Secretary	Officer	5 611 Value: $6K
Apr 01, 2026 Sell	Class A Common Stock F-InKind	Agafonova Nataliya Chief Medical Officer	Officer	13 145 Value: $14.7K
Apr 01, 2026 Sell	Class A Common Stock F-InKind	Willard Stephen H Chief Executive Officer	CEO / President	4 740 Value: $5K
Mar 02, 2026 Buy	Class A Common Stock A-Award	Willard Stephen H Chief Executive Officer	CEO / President	200 000 Value: $109.0K
Mar 02, 2026 Buy	Class A Common Stock A-Award	Willard Stephen H Chief Executive Officer	CEO / President	200 000 Value: $109.0K
Mar 02, 2026 Buy	Stock Option (right to buy) A-Award	Willard Stephen H Chief Executive Officer	CEO / President	200 000 Value: $109.0K
Mar 02, 2026 Sell	Class A Common Stock F-InKind	Willard Stephen H Chief Executive Officer	CEO / President	105 533 Value: $57.5K
Feb 11, 2026 Buy	Class A Common Stock	Willard Stephen H Chief Executive Officer	CEO / President	0 Value: $0
Jan 02, 2026 Sell	Class A Common Stock F-InKind	Powell James Nathaniel Chief Executive Officer	CEO / President	2 464 Value: $1K
Jan 02, 2026 Sell	Class A Common Stock F-InKind	Blass Devin CTO & SVP Of Cmc	Officer	10 700 Value: $6K
Jan 02, 2026 Sell	Class A Common Stock F-InKind	Agafonova Nataliya Chief Medical Officer	Officer	10 250 Value: $6K
Jan 02, 2026 Sell	Class A Common Stock F-InKind	Lehr Paul T General Counsel, Secretary	Officer	6 952 Value: $4K
Jan 02, 2026 Sell	Class A Common Stock F-InKind	Locklear Lisa Chief Financial Officer	C-Suite Officer	10 250 Value: $6K
Oct 01, 2025 Buy	Class A Common Stock	Paletta George A. Jr. Director	Director	0 Value: $0
Oct 01, 2025 Buy	Class A Common Stock A-Award	Paletta George A. Jr. Director	Director	34 000 Value: $25.2K
Oct 01, 2025 Sell	Class A Common Stock F-InKind	Agafonova Nataliya Chief Medical Officer	Officer	11 883 Value: $9K
Oct 01, 2025 Sell	Class A Common Stock F-InKind	Powell James Nathaniel Chief Executive Officer	CEO / President	2 389 Value: $2K
Oct 01, 2025 Sell	Class A Common Stock F-InKind	Lehr Paul T General Counsel, Secretary	Officer	4 944 Value: $4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT LONGEVERON INC.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, a...

Read Full Profile Here